We take issue with the stance that postoperative radioiodine remnant ablation should be applied ubiquitously as adjuvant therapy in patients with well-differentiated thyroid carcinoma. In this article, we state the reasons that we believe a compelling case can be made against ablation in most patients.
No takes yet. Share an insight, caveat, or question.
Hay et al. (2008) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: